Aquestive Therapeutics (NASDAQ:AQST) Stock Rating Reaffirmed by Leerink Partners

Aquestive Therapeutics (NASDAQ:AQST)‘s stock had its “outperform” rating reaffirmed by analysts at Leerink Partners in a report released on Monday, Benzinga reports. They currently have a $12.00 target price on the stock, up from their prior target price of $10.00. Leerink Partners’ target price would suggest a potential upside of 152.10% from the company’s current price.

Several other brokerages have also commented on AQST. JMP Securities restated a “market outperform” rating and issued a $9.00 price objective on shares of Aquestive Therapeutics in a report on Monday, August 12th. HC Wainwright increased their price target on shares of Aquestive Therapeutics from $9.00 to $10.00 and gave the stock a “buy” rating in a research note on Monday. Six investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Aquestive Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $8.67.

Aquestive Therapeutics Stock Down 4.4 %

Shares of Aquestive Therapeutics stock opened at $4.76 on Monday. The company’s fifty day simple moving average is $4.26 and its two-hundred day simple moving average is $3.68. Aquestive Therapeutics has a 12-month low of $1.25 and a 12-month high of $6.23. The firm has a market cap of $433.35 million, a PE ratio of -11.33 and a beta of 2.84.

Aquestive Therapeutics (NASDAQ:AQST) last posted its earnings results on Tuesday, August 6th. The company reported ($0.03) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.08. The business had revenue of $20.10 million during the quarter, compared to the consensus estimate of $12.62 million. During the same period in the previous year, the business earned ($0.10) earnings per share. As a group, sell-side analysts expect that Aquestive Therapeutics will post -0.47 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Aquestive Therapeutics

Several hedge funds have recently bought and sold shares of AQST. Victory Capital Management Inc. purchased a new position in shares of Aquestive Therapeutics during the second quarter valued at approximately $27,000. PFG Investments LLC increased its holdings in shares of Aquestive Therapeutics by 22.9% during the second quarter. PFG Investments LLC now owns 59,000 shares of the company’s stock valued at $153,000 after acquiring an additional 11,000 shares in the last quarter. SG Americas Securities LLC purchased a new position in shares of Aquestive Therapeutics in the 1st quarter worth about $54,000. Financial Advocates Investment Management boosted its stake in Aquestive Therapeutics by 70.0% in the 2nd quarter. Financial Advocates Investment Management now owns 34,000 shares of the company’s stock worth $88,000 after purchasing an additional 14,000 shares in the last quarter. Finally, Lazard Asset Management LLC grew its position in Aquestive Therapeutics by 115.5% during the 1st quarter. Lazard Asset Management LLC now owns 29,112 shares of the company’s stock valued at $124,000 after purchasing an additional 15,601 shares during the last quarter. Institutional investors own 32.45% of the company’s stock.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.